New drug combo aims to keep blood cancer at bay after transplant
NCT ID NCT02420860
Summary
This study is testing whether adding the immunotherapy drug elotuzumab to standard maintenance therapy (lenalidomide) helps keep multiple myeloma from returning after a patient's own stem cell transplant. The trial involves 113 patients who have recently undergone transplant for newly diagnosed multiple myeloma. Researchers will measure how long patients remain cancer-free and monitor side effects of the two-drug combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.